abnormal xenobiotic pharmacokinetics_Cyp2a5<tm1Ding>/Cyp2a5<tm1Ding>

http://metadb.riken.jp/0008875IC57BL6C57BL6JCyp2a5tm1DingCyp2a5tm1DingCyp2a5tm1Ding

abnormal xenobiotic pharmacokinetics_Cyp2a5<tm1Ding>/Cyp2a5<tm1Ding>

表現型アノテーション

MGI marker

http://metadb.riken.jp/db/mgi_rdf/variant_of

• cytochrome P450, family 2, subfamily a, polypeptide 5
  http://metadb.riken.jp/db/mgi_rdf/MGI:88597

遺伝子型

http://metadb.riken.jp/db/mgi_rdf/allele_composition

• Cyp2a5<tm1Ding>/Cyp2a5<tm1Ding>

アレルシンボル

http://metadb.riken.jp/db/mgi_rdf/allele_symbol

• Cyp2a5<tm1Ding>

遺伝的背景

http://metadb.riken.jp/db/mgi_rdf/genetic_background

• involves: C57BL/6 * C57BL/6J

MP annotation

http://metadb.riken.jp/db/bioresource_schema/brs_indicatesPhenotype

• abnormal xenobiotic pharmacokinetics
  http://purl.obolibrary.org/obo/MP_0008875

文献

http://purl.org/net/cito/citesAsAuthority

• Xin. Zhou, et.al., Role of CYP2A5 in the clearance of nicotine and cotinine: insights from studies on a Cyp2a5-null mouse model., The Journal of pharmacology and experimental therapeutics, 2010, 332
  http://rdf.ncbi.nlm.nih.gov/pubmed/19923441